Cabonrom 20mg Cabozantinib Tablets offer targeted therapy for advanced cancers, including renal cell carcinoma (RCC) and medullary thyroid carcinoma (MTC). Cabozantinib belongs to a class of medications known as tyrosine kinase inhibitors (TKIs), which work by blocking enzymes that contribute to tumor growth and spread.

Each tablet contains 20mg of Cabozantinib, designed to inhibit multiple receptor pathways such as VEGFR, MET, and AXL. This action reduces the blood supply to tumors and interferes with cancer cell proliferation. Doctors often prescribe Cabonrom to patients who have shown disease progression despite prior treatment options.

Patients typically take Cabonrom once daily, at least one hour before or two hours after eating. Your oncologist will determine the appropriate dosage based on your medical condition and treatment response. It is important to follow your doctor’s instructions carefully and avoid adjusting the dose on your own.

Swallow the tablet whole with water. Do not crush, split, or chew the tablet. Regular monitoring of blood pressure, liver function, and electrolyte levels is necessary during treatment with Cabozantinib.

Store the medication at room temperature, away from moisture, heat, and direct sunlight. Always keep it out of the reach of children and pets.